Cue Biopharma, Inc. (CUE) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to the QBioPharma's novel biologics portfolio. At this time, all attendees are in a listen-only mode. Today's call will focus on a review of Q's novel biologics development platform for immobilizing the immune system. Joining me on today's call is QBioPharma's chief executive officer, Dan Passari, two recognized T-cell researchers, Dr. Richard DiPaolo and Dr. Andy Cope, and members of Q Management. Please note that this presentation and discussion is being recorded and will be available in the Investors and Media section of the company's website at qbiopharma.com for the next 30 days. Additionally, some of the statements we make on this call will include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those stated or implied by these forward-looking statements due to important risks and uncertainties associated with the company's business, including those set forth in the risk factors and in management's discussion and analysis of financial condition and results of operations section of QBioPharma's Annual report on Form 10-K for the year ended December 31, 2024, filed on March 31, 2025. It's quarterly report on Form 10-Q filed on May 12, 2025, and any other filings that we may make with the SEC. In addition, any forward-looking statements represent our views as of today, May 15, 2025. Q undertakes no obligation to revise or update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments, or otherwise, after the date of this conference call. Now, I would like to hand the call over to Q's CEO, Dan Passeri. Dan? Thank you, Tara, and good morning, everyo...